ZMapp reverses advanced Ebola in monkeys

In a primate study, ZMapp from Mapp Biopharmaceutical Inc. (San Diego, Calif.) reversed 100% of advanced Ebola cases. A research group led by Gary Kobinger of the University of Manitoba that included Mapp CEO Larry Zeitlin published a paper in Nature showing all 18 rhesus monkeys survived when treated with ZMapp up to five days post infection, with severe symptoms reversed.

ZMapp combines components of mAbs targeting Ebola glycoproteins GP1 and GP2 from Mapp's MB-003 and ZMab from Defyrus Inc. (Toronto, Ontario). Preclinical work describing the effect of MB-003 on Ebola infection in nonhuman primates was published in Science Translational Medicine in 2013 and work describing the effect of ZMab was published in the journal in 2012 (see SciBX: Science Business eXchange, July 26, 2012). ...